Number of Episodes Can Be Used as a Disease Activity Measure in Familial Mediterranean Fever

Creative Commons License

Piskin D., Arici Z. S., Konukbay D., Romano M., MAKAY B., Ayaz N., ...Daha Fazla

Frontiers in Pediatrics, cilt.10, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3389/fped.2022.822473
  • Dergi Adı: Frontiers in Pediatrics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals
  • Anahtar Kelimeler: Familial Mediterranean fever, disease activity, quality of life, patient reported outcomes, convergent validity, QUALITY-OF-LIFE, JUVENILE IDIOPATHIC ARTHRITIS, SYSTEMIC-LUPUS-ERYTHEMATOSUS, FATIGUE, CHILDREN, DEPRESSION, RECOMMENDATIONS, PERFORMANCE, VALIDATION, MANAGEMENT
  • Erciyes Üniversitesi Adresli: Evet

Özet

Copyright © 2022 Piskin, Arici, Konukbay, Romano, Makay, Ayaz, Bilginer, Berard, Poyrazoglu, Kasapcopur, Laxer, Speechley and Demirkaya.Objective: To evaluate the number of episodes in the past 12 months as an indicator of the overall disease activity status in Familial Mediterranean fever (FMF). Methods: In this cross-sectional study, patients were recruited from tertiary pediatric hospitals. Demographic data, main clinical symptoms of the episodes, treatment modalities, and genetic mutations were recorded. The patients were grouped as no episodes (Group 1), 1–4 episodes (Group 2), and more than 4 episodes (Group 3) according to the number of episodes in the past 12 months. The Pediatric Quality Life Inventory (PedsQL), the Children’s Depression Inventory (CDI), and the Wong-Baker FACES Pain Rating Scale (FACES) scores were compared between groups. Concurrent validity between the number of episodes and the patient-reported outcome measures (PROMs) was assessed using Spearman’s rank correlation coefficient (ρ). Results: A total of 239 patients were included. There were 74 patients (31%) in Group 1, 99 (41.4%) in Group 2, and 66 (27.6%) in Group 3. Groups were similar according to age, age at diagnosis, gender, consanguinity, family history, history of amyloidosis, clinical symptoms, and in terms of allele frequency (p > 0.05). According to PROMs completed by parents, moderate correlations were found between the number of episodes and the PedsQL score (ρ = −0.48; 95% CI = −0.58 to −0.35, p < 0.001) and between the number of episodes and the Wong-Baker FACES score (ρ = 0.47, 95% CI = 0.35–0.57, p < 0.001). Conclusion: The number of episodes was positively and moderately correlated with patient- and parent-reported outcomes in our cohort. The number of episodes in patients with FMF can be used as a single measure to assess disease activity.